-
公开(公告)号：DK1685152T3
公开(公告)日：2012-07-30
申请号：DK04817825
申请日：2004-11-12
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
-
公开(公告)号：ES2385484T3
公开(公告)日：2012-07-25
申请号：ES04817825
申请日：2004-11-12
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
Abstract: Un anticuerpo, o porción de unión al antígeno del mismo, capaz de unirse IL-18 humana, donde dicho anticuerpo, o porción de unión al antígeno del mismo, comprende una CDR-H1 que tiene los Residuos 31-35 del SEQ ID NO: 6; una CDR-H2 que tiene los Residuos 50-66 del SEQ ID NO: 6; una CDR-H3 que tiene los Residuos 99-110 del SEQ ID NO: 6; una CDR-L1 que tiene los Residuos 24-34 del SEQ ID NO: 7; una CDR-L2 que tiene los Residuos 50-56 del SEQ ID NO: 7; y una CDR-L3 que tiene los Residuos 89-98 del SEQ ID NO: 7.
-
公开(公告)号：PT1685152E
公开(公告)日：2012-07-23
申请号：PT04817825
申请日：2004-11-12
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , VOSS JEFFREY W , LABKOVSKY BORIS , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
-
公开(公告)号：ECSP10010657A
公开(公告)日：2011-02-28
申请号：ECSP10010657
申请日：2010-12-03
Applicant: ABBOTT LAB
Inventor： WOLLER KEVIN ROGER , WISHART NEIL , FRIEDMAN MICHAEL , CALDERWOOD DAVID , ARGIRIADI MARIA A , WALLACE GRIER A , ERICSSON ANNA M , FIAMENGO BRYAN A , FRANK KRISTINE E , GEORGE DAWN M , GOEDKEN ERIK R , JOSEPHSOHN NATHAN S , LI BIQIN C , MORYTKO MICHAEL J , STEWART KENT D , VOSS JEFFREY W , WANG LU
IPC: A01N43/42
Abstract: La invención proporciona un compuesto de la Formula (I)Formula (I)sales farmacéuticamente aceptables, metabolitos biológicamente activos, estereoisómeros eisómeros de estos en donde las variables están definidas en este documento. Los compuestos de la invención son útiles para el tratamiento de condiciones inmunológicas y oncológicas.
-
公开(公告)号：CA2805859A1
公开(公告)日：2005-05-26
申请号：CA2805859
申请日：2004-11-12
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
Patent Agency Ranking
公开(公告)号：AU2004290073A1
公开(公告)日：2005-05-26
申请号：AU2004290073
申请日：2004-11-12
Applicant: ABBOTT LAB
Inventor： JIA XIAO-CHI , WIELER JAMES , GREEN LARRY , HEDBERG BRAD , LABKOVSKY BORIS , BABCOOK JOHN , KANG JASPAL SINGH , VOSS JEFFREY W , GHAYUR TARIQ
Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
公开(公告)号：BRPI0915374A2
公开(公告)日：2015-08-04
申请号：BRPI0915374
申请日：2009-06-09
Applicant: ABBOTT LAB
Inventor： WISHART NEIL , ARGIRIADI MARIA A , CALDERWOOD DAVID J , ERICSSON ANNA M , FIAMENGO BRYAN A , FRANK KRISTINE E , FRIEDMAN MICHAEL , GEORGE DAWN M , GOEDKEN ERIC R , JOSEPHSOHN NATHAN S , LI BIQUIN C , MORYTKO MICHAEL J , STEWART KENT D , VOSS JEFFREY W , WALLACE GRIER A , WANG LU , WOLLER KEVIN R
IPC: A01N43/42
-
公开(公告)号：MX2012006311A
公开(公告)日：2012-09-12
申请号：MX2012006311
申请日：2010-12-01
Applicant: ABBOTT LAB
Inventor： VOSS JEFFREY W , WISHART NEIL , ERICSSON ANNA M , GEORGE DAWN M , WALLACE GRIER A , STEWART KENT D , FRANK KRISTINE E , MORYTKO MICHAEL J , ARGIRIADI MARIA A , JOSEPHSOHN NATHAN S , FRIEDMAN MICHAEL , WOLLER KEVIN R , WANG LU , GOEDKEN ERIC R , LI BIQIN C , CALDERWOOD DAVID J , FIAMENGO BRYAN A
IPC: A01N43/58
Abstract: La invención proporciona los compuestos de la Fórmula (I) y Fórmula (II), sales farmacéuticamente aceptables, profármacos, metabolitos biológicamente activos, estereoisómeros e isómeros de los mismos, en donde las variables son definidas en la presente. Los compuesto de la invención son útiles para tratar enfermedades inmunológicas y oncológicas.
-
公开(公告)号：AT555130T
公开(公告)日：2012-05-15
申请号：AT04817825
申请日：2004-11-12
Applicant: ABBOTT LAB
Inventor： GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
Abstract: The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
-
公开(公告)号：CA2781010A1
公开(公告)日：2011-06-09
申请号：CA2781010
申请日：2010-12-01
Applicant: ABBOTT LAB
Inventor： WISHART NEIL , ARGIRIADI MARIA A , BREINLINGER ERIC C , CALDERWOOD DAVID J , ERICSSON ANNA M , FIAMENGO BRYAN A , FRANK KRISTINE E , FRIEDMAN MICHAEL , GEORGE DAWN M , GOEDKEN ERIC R , JOSEPHSOHN NATHAN S , LI BIQUIN C , MORYTKO MICHAEL J , MULLEN KELLY D , SOMAL GAGANDEEP , STEWART KENT D , VOSS JEFFREY W , WALLACE GRIER A , WANG LU , WOLLER KEVIN R , HOEMANN MICHAEL Z
IPC: C07D471/14 , C07D487/14 , C07D498/14 , C07D513/14 , C07D519/00
Abstract: The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
-
-
-
-
-
-
-
-
-
Search Results
48
records
(took 0.079 seconds)
